Novo Holdings A/S - Feb 9, 2024 Form 4 Insider Report for Metagenomi, Inc. (MGX)

Role
10%+ Owner
Signature
/s/ Barbara Fiorini Due, General Counsel, Finance & Operations
Stock symbol
MGX
Transactions as of
Feb 9, 2024
Transactions value $
$13,025,000
Form type
4
Date filed
2/15/2024, 08:38 PM
Previous filing
Feb 8, 2024
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGX COMMON STOCK Purchase $1.03M +100K $10.25* 100K Feb 9, 2024 Direct
transaction MGX COMMON STOCK Conversion of derivative security +839K +839.18% 939K Feb 13, 2024 Direct F1
transaction MGX COMMON STOCK Purchase $12M +800K +85.18% $15.00* 1.74M Feb 13, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGX SERIES B PREFERRED STOCK Conversion of derivative security -147K -100% 0 Feb 13, 2024 COMMON STOCK 147K Direct F1
transaction MGX SERIES B-1 PREFERRED STOCK Conversion of derivative security -692K -100% 0 Feb 13, 2024 COMMON STOCK 692K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Novo Holdings A/S is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date.
F2 Represents a purchase from the underwriters in the Issuer's initial public offering.